Marvel Biosciences Reports MB-204 Results in Shank3 Mouse Study

Marvel Biosciences said high-dose MB-204 returned six measured behavioural endpoints to wild-type levels in a preclinical Shank3 mouse study. Istradefylline did not normalize those measures; the company is preparing for a Phase 1 trial.